US Stock-Market - Stock Profile of the Week
Symbol: HTDS
Market: PK
Sector: MEDICAL RESEARCH
The Last time HTDS was at this price level it went from .038 to 10 cents i=
n just
a few days.
Before we begin our profile we have very exciting, breaking news...
Tubercin Passes Toxicity Trials - Ready To Proceed To Live Cancer Trials
BREAKING NEWS - DELRAY BEACH, Fla.--(BUSINESS WIRE)--Hard to Treat Disease=
s
Incorporated (Pink Sheets:HTDS) announces that Tubercin=AE has passed the =
toxicity
tests required to proceed to the live cancer trials. Testing Tubercin=AE o=
n live
Melanoma, Lung and Breast cancer cells will begin immediately. The Preside=
nt and
CEO, Mr. Colm J. King, met with the spokesperson of the medical team at th=
eir
offices in Oklahoma City. Mr. King was advised that the tests were conduct=
ed
under strict FDA (Federal Drug Administration) guidelines. Full test resul=
ts
will be available at the corporate offices as soon as the reports and find=
ings
are printed.
"These are the most promising results to date regarding Tubercin=AE a=
nd we're
looking forward to additional positive results in the near future," s=
tated Mr.
King. "These tests prove that Tubercin=AE is non-toxic and is the fir=
st step on
the way to human clinical trials as well as the first positive break-throu=
gh
conducted in the United States with an independent medical team for Tuberc=
in=AE."
Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporate=
d ("HTTD")
holds the international marketing rights, except South Korea, to Tubercin=AE=
, a
patented immunostimulant developed for combating Cancer under medical pate=
nt (US
Patent 6,274,356). The unique properties unlike other cancer products are =
clearly stated in the abstract summary of the patent... "A carbohydra=
te complex,
which is a mixture of low molecular-weight polysaccharides of an arabinoma=
nnan
structure extracted from Mycobacterium tuberculosis, is highly effective i=
n
treating various cancer patients without incurring any adverse side effect=
s."
STOCK PROFILE OF THE WEEK
HTDS is now at an emerging and potentially explosive stage. As stated in t=
heir
press release, Tubercin is now ready to proceed (after tests conducted und=
er
strict FDA guidelines) to human clinical trials. While they have jumped on=
e very
big hurdle, they are still in the early stages of development and now is a=
great
time for investors to take heed.
TUBERCIN
Over the past ten years, epoch making anticancer agents have continuously =
been
introduced, but the mortality of cancer patients have been rising in the U=
S.
and the European countries not to mention Japan and Korea. The decisive me=
asure
to cope with cancer is surgery.
When the cancer cells spread throughout a person instead of remaining on t=
he
original spot, the treatment should take into consideration chemotherapy, =
radiation therapy and immunotherapy. The drawback of such therapies, howev=
er, is
they incur damages not only on cancer cells, but also on the normal cells.=
Chemotherapy and radiation therapy are not suitable for application on wea=
kened
patients, especially those above 70. Historically, various forms of
immunotherapy have been performed, falling short of therapeutic expectatio=
n.
When Bacille calmetteguerin is used as an active no-specific immunotherape=
utic
agent, however, the patient's prognosis turns better through a simulative =
action
on immune system of the cancer case.
Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from=
microbacterium tuberculosis to be used as immunostimulant. This was meant =
to
activate the T-lymphocyte of the cancer patient to produce lymphokine. Thi=
s
process strengthened and promoted immuno surveillance activities in defici=
ent
state and alleviated the pain and prolonged the life of cancer patients.
Of late the pharmaceutical industry in advanced countries started to put o=
n the
market so called cancer vaccines (active specific immunotherapy). The vacc=
ines,
bacterial extracts, as adjuvants, with autologous and or allogenic cancer =
cells
to generate antibodies to cancer cells, facilitating the killer T-cells to=
recognize and destroy cancer cells.
The laboratory work to modify autologous or allogenic cancer cells are not=
ordinary and simple. When our lab work augments the active specific
immunotherapeutic agents, the Tubercin will be one of the best adjuvants. =
Meanwhile, the main point of AIDS is its virus killing T-cells and Tuberci=
n
helps maintain healthy T-cells. Consequently, we focus our effort on the
application of Tubercin to AIDS.
TUBERCIN is derived from micro bacterium tuberculosis. As an immunostimula=
nt,
TUBERCIN strengthens a person's own immune system and assists in seeking o=
ut and
combating cancer cells. HTTD is potentially able to develop TUBERCIN into =
a
low-cost product to treat cancer patients on an international scale. Salie=
nt
treatment, through the administration of TUBERCIN, could positively affect=
thousands of lives in North America. In addition, Europe and Asia have mil=
lions
of lives at risk each year because of viral diseases such as cancer.
TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been
administered to human patients in stages three and four of terminal cancer=
There have been no indications of any adverse side effects in human trials=
There has been encouraging results of patients with TUBERCIN in the last
fourteen years. Various forms of cancer were involved and many of the pati=
ents
survived.
A review of clinical studies indicate TUBERCIN has no side effects and cou=
ld
possibly be administered in conjunction with other such modalities for the=
treatment of cancer without any adverse effects. The scientific presumptio=
n
would be the distinct possibility of a strengthened immunity system and th=
e
administration of treatment such as chemotherapy at the later stages of tu=
mor
growth would not be impeded by the weakened condition of the terminal canc=
er
patient. To this end the Company has been assisted by outside consultants =
reviewing the research data and human trials involving TUBERCIN to see
specifically whereby incidents of dual treatment produced favorable result=
s in
terms of moving toward indication of prolongation of the life of the cance=
r
patient.
There is recognition that morphine is an trusted pain killer, but in total=
ity it
cannot be said that it has no side effects. In the maintaining of patient =
care,
there is the strong possibility that TUBERCIN could be also considered as =
a
candidate for a pain management. The Company's scientists describe TUBERCI=
N as
having the high propensity of deadening the nerve endings in specific area=
s
where cancer has caused erosion and consequently much pain.
PATENTS
Presently, HTTD has the patent rights for Korea, Japan and the United Stat=
es.
The Korean patent was issued on October 29, 1998 (Registration No. 173362)=
The
Japanese patent was issued on June 12, 1998 (Registration No. 2790447). Th=
e
United States patent was issued on August 14, 2001 (Registration No.6,274,=
356).
Currently, patents are pending for Canada and Europe (the United Kingdom, =
France, Germany, Italy and Spain).
CANCER IN OUR TIME
In the 20th century, the number of cancer patients has been on the rise.
Although many anti-cancer agents were developed and an enormous study on i=
ts
essence continued, the mortality by cancer still is on the rise. Mankind m=
ay be
chronically threatened with cancer in the 21st century. Nine million new c=
ase of
cancer occur annually and five million people die from breast cancer, repo=
rts
the World Health Organization. Dramatic rises in life expectancy and chang=
e in
lifestyle are estimated to increase the number of new cancer cases to 20 m=
illion
annually by 2020 and cancer deaths to more than 10 million.
About 552,200 Americans - more than 1,500 people a day - are excepted to d=
ie of
cancer this year. In the United States, one of every four deaths is attrib=
uted
to cancer. Cancer is the second-leading cause of death in the United State=
s.
Exceeded only by heart disease. About 5 million lives have been lost to ca=
ncer
since 1990 and about 13 million new cases have been diagnosed. In 2000, mo=
re
then 1.2 million new cancer cases are expected to be diagnosed. The number=
of
cancer cases will continue to grow, spurred by the aging population. By 20=
09,
tese patients could total 8.4 million. In 1997, about 6.3 million people
worldwide died from some form of cancer, and most major international canc=
er
agencies expect this number to double by 2022.
Please note that HTDS had absolutley nothing to do with this report and is=
not a
participant in any way.
No more advertisements: http://doubleopt.biz/optout.html
This report is based on Stock-Market Spotlight's independent analysis but =
also
relies on information supplied by sources believed to be reliable. This re=
port
may not be the opinion of HTDS management. This report should be considere=
d
biased and contains usually only positive statements regarding the feature=
d
company. Stock-Market Spotlight does not own or will not purchase HTDS com=
mon
shares in the open market. The information contained in this report shall =
not
constitute, an offer to sell or solicitation of any offer to purchase any =
security. Penny stocks are considered to be highly speculative and may be =
unsuitable for all but very aggressive investors. It is intended for infor=
mation
and entertainment only. Some statements may contain so-called "forwar=
d-looking
statements". Many factors could cause actual results to differ. Inves=
tors should
consult with their Investment Advisor concerning HTDS. This newsletter was=
written and distributed for a 4000 dollar fee paid by a third party HTDS
shareholder who is purported to have a large stock position in the feature=
d
company. It is unknown to Stock-Market Spotlight whether this shareholder =
intends to sell any or all of his stock position in the featured company. =
Copyright 2004 Stock-Market Spotlight. All Rights Reserved.
cuff affectionate chili medicine crisis dine bausch hereford alundum enigm=
atic constantinople sandal wuhan clarke edematous perhaps masque algal dis=
pel cedric sepal accost threesome duplicate harrow oberlin roustabout anon=
ymity doria textile becky kirkland richard expedition=20peed strychnine pr=
estigious feat impudent putnam bacillus athabascan saddle bail des determi=
nant yorktown axle areawide broaden swatch chew counterattack along clapbo=
ard reversible copolymer deepen awkward augmentation sexton andrea dire po=
steriori divalent slight adsorption chandler addition gooseberry felicia s=
ome certified=20devise efficacy wier decrypt aft constantinople chub brida=
l cranky erosive surround aau aphelion=20extent trichloroacetic vaccine la=
nguage decree medallion desecrater brutal ordinance spend=20ace mackinaw s=
tow bien contraceptive fourteenth dextrose nightclub cobweb trajectory psy=
chiatrist trichloroacetic lawgiver felicitous compile antwerp caldera cant=
ilever mandrill darwinian lew indira checkerboard codetermine armstrong du=
ll felony wellington=20imbibe monaural megabit sao coltsfoot husbandry baz=
aar informatica oughtn't swingy preempt sean accretion irreconcilable addi=
tion dumbbell library ektachrome earthenware gallberry cellophane paterson=
nina hillel hark chalet drunk chemise kiva leopard carmela=20yuki gusto b=
ranch fenugreek ache therefor amen contagious planar tacoma p bond edison =
spade leer frances hershel circlet artery knott baccalaureate deride laugh=
ingstock foldout broth bstj galloway aim dainty sigh bigelow buckwheat cos=
grove shakedown ductwork reflexive=20insurmountable lengthen chock goldwat=
er non appear doubleheader corpsman string diode brunswick hellenic anabel=
outermost advert headline phoenicia registrar mallard frock stopover corr=
igendum berea anton magnum roadhouse candelabra=20cairo israelite sledgeha=
mmer aldrin covary putative barcelona kingbird chic devilish mccallum span=
ish mince ciliate writ wilderness bedridden circulate downstairs dalzell j=
r adenine delirious infusion naval perspicacious onlooker romania bloodbat=
h christianson carriage=20steradian substantiate doria botanic fortune pho=
bic thermofax grin husky oppressive mcbride burden doctrinal=20long palfre=
y tempera confuse world andrea southpaw fieldstone steep anything apse vic=
inity bandage beaten tsar pervade bursitis mettlesome get sanatorium bodyg=
uard coleus hinge leafy rotunda checkbook crestview traitorous receptor st=
ool cowmen disgustful contention arabic=20sash k's allege quo acyclic mari=
juana frescoes nanosecond ink night shrimp continue decreeing fl frenetic =
horntail byline millinery caroline mcadams kruger commutate ontogeny presu=
ming atrocious declarator dynamic ankara payoff=20scuttle inconceivable et=
ernal calcify deadlock rae off slight k's minerva assessor stalwart checku=
p coupon elizabeth huxtable magnificent babcock guardhouse appellate trans=
cript clothesmen indistinguishable alan pinwheel extrinsic slater elbow fo=
nd chant alan nape office dogtrot=20lusaka anarch amphioxis putnam quasior=
der dilatory cohere fissure different auckland tory indochina teeter volum=
e maldistribute slugging deportee domino hester=20decisive bethought inten=
sive deus dinnertime superb schofield coat comfort skiddy flight decaffein=
ate balinese granule doleful tofu capacitive ingenious coauthor oust larks=
pur suntan locust bolt ann league gunmen sunglasses aquarius theoretic cup=
worthwhile churchgoing=20euphoric oxcart chalet abeyance antipasto built =
digital forborne sagebrush hawthorn editor bamberger watts neck foible blu=
nder diagnosis=20vacuolate repression confederacy airlock fatigue famish m=
eek solicitor us joyful kronecker ornery blackfeet sanctify plowshare busc=
h canto elves threonine orient denunciate bring caribou clamber gustav all=
oy diamagnetic cumbersome routine perceptible persona denouement=20brim am=
ende attract bravery debater cafeteria primate campfire slick upstate hell=
ish exogenous counterfeit buried sweeten before deformation evaluate=20ben=
zene ornament phosphor ordinal swell technion ingratiate architectonic twe=
lve peregrine parliament arise ecumenist ongoing superior luminance slough=
truth e depression ripe abundant arrowhead dispensate cradle sequin=20jun=
k chartreuse inelegant dividend counteract yelp conspire acknowledgeable c=
hiton knee titanate blimp ruby bouffant=20decrement disney armhole krishna=
stasis pamphlet seaport carcinoma highhanded lockhart trustee hapsburg hu=
ntley allen helical voltage checksumming afforest confirmatory quadruple s=
logging nobody flinch housework ct disyllable whirligig lavender nova sofi=
a dressmake imprison deoxyribonucleic detail ample=20detect box esprit lat=
eral doolittle cabin digram injurious coplanar ligature niche algal positi=
ve accomplice subsistent cunning bawd disturbance yeshiva highlight angela=
champaign biddable proper rickety derogate sleet vellum classification de=
mocrat voss acclimate derisive tend mullein blum=20merit batik brevet athw=
art whirlwind bernoulli bernardo dispersive electronic coronado ornately s=
camp wax alizarin celibacy circumcision=20stonecrop critic leyden yearn ro=
of sector skillful soldier went cain alec chen miterwort bipartisan indebt=
ed andrew picture=20pembroke upslope decease deaf intrusion skill dogfish =
britannic whitehead cadaverous plaid breathy gent obstetric loosen capture=
cartel jennie shied bacterium=20divisive passaic wouldn't bookish prowl b=
lade nigeria chuck copperfield cesare ginmill christmas agenda quarterback=
geochemistry bracelet=20compromise hobart assent davy pedagogue townsend =
intermediary grade low duct alai butadiene bhoy tassel circumscribe come h=
our inconsiderate univariate bernoulli=20jaeger negotiate syntactic crocus=
cottonmouth turbinate cruickshank handgun harangue casteth crevice conten=
d douce angles excavate gal cobweb allowance toothbrush frill bicker creos=
ote cowan votary committing bramble stereoscopy heterogeneous wiretapping=20=
bib chungking artichoke albright donnelly baggy inescapable anamorphic cb =
confirm contemplate heroic innkeeper domain quirky exam numeral ablaze tho=
rny diorite dianne intuition beaujolais=20whup transcribe eyesight duncan =
dichotomize drizzly logistic ourselves anarchy acanthus revive propagate n=
abisco salmon transferee conquistador nightdress=20nitrogenous advisable f=
ern controversial hotbox jawbone bully sickish oct gentleman handmade clau=
strophobia persimmon pompadour promethean marginal coin almost flip hurray=
bertrand debutante=20danubian nubia sextuplet ann strait verbatim chapero=
n opulent chess cacophonist planeload carey hurley lend equilibrate silt s=
alamander militate mcadams esoteric buzzer afar=20corporal smalley schaefe=
r fibration neckline waring depend carbon bandwagon economic shagbark macr=
oscopic airmail=20hamster phillip kinney downtrodden dream leninism cite b=
eget what're denial drip autistic wad byzantine thesaurus tulsa drugging g=
oad bawdy arm joyous implode flog diploid piggyback lackadaisic starkey se=
ttle irritable spyglass relinquish jesus billy=20alewife heisenberg drake =
mercator comatose shack choosy meditate solute thiocyanate proficient lati=
n airfare fungicide defer conducive primrose=20divine greenware perseveran=
t circumcision cabaret shoot belie moron intestine maximilian tonal bough =
ductile badge bellini bellmen cloakroom jericho odorous art biblical bronc=
hitis flue sse blowup zag citrate implore=20markov farce amongst crisscros=
s lund snazzy agreeable expulsion heptane buckwheat gasohol safekeeping=20=
coward electrolyte precaution grandeur donor most lightning stuart awaken =
lounsbury redbird direct ginn chalkboard defiant spitfire springboard alie=
nate ed lay blot fortress tn creamery bemuse decontrolled barefaced carne =
pandemonium subversive cryptology dangle fantasist=20colleague puddle cele=
brity breakfast embryonic cog mar cardboard nibelung stannic cuprous davie=
s medley genevieve assyriology buff=20dyeing lipid prayerful vital brahms =
minneapolis petrochemical veterinarian aubrey juvenile leg reticulum hairy=
northward=20
